It’s an exciting time for gene therapy! The FDA expects 40-60 gene therapy products to be approved in the US alone before 2030. So, the medical affairs role has never been more vital in ensuring that the next generation of gene therapy products are delivered to patients.
Enter: the Gene Therapy Medical Affairs digital summit, February 9-11 2021. Set to unite the industry’s leading medical affairs, medical science, market access and HEOR experts, this inaugural meeting will be addressing the full A-Z of medical affairs, covering everything from medical communication, education and clinical development to market access, launch readiness and long term follow up challenges.
Over the course of three days, the summit will be live streaming presentations and interactive workshops from 18 of the biggest names in this space. They include Kent Christopherson, Senior Director US Medical Affairs, Orchard Therapeutics; Stephen Kagan, Global Medical Lead, Gene Therapy Platform Medical Affairs, Pfizer; Eileen Sawyer, Vice President Global Medical Affairs, UniQure; Martjin Moransard, Director, Medical Training EMEA, Novartis Gene Therapy and more.
They’ll be discussing amplifying medical affairs effectiveness through internal and external partnerships, maximizing patient engagement through the medical affairs role, medical science education and learning, launch readiness (making or breaking a successful launch), optimizing market access strategy, the role of medical affairs in clinical development and evidence generation and long term follow up.
Plus, the discussions will be taken even further in the pre-conference workshop day focusing on what it takes for effective medical affairs management in the rare diseases gene therapy space (lead by Tom Pulles, Vice President Medical Affairs, Ultragenyx) and what it takes to build an effective medical affairs team in the gene therapy field (lead by Kent Christopherson, Senior Director US Medical Affairs, Orchard Therapeutics and Thomas Board, Senior Medical Science Liaison, Neurocrine Biosciences).
In this brand-new style of digital meeting, all sessions are specifically designed to achieve maximum engagement and value for all attending delegates:
- Discover sessions are where the speakers will share stories and case studies of how they have solved their more pressing challenges
- Develop sessions provide the opportunity for delegates to ask questions and spark conversations in a virtual room of experts and their industry peers
- Action sessions are designed to help delegates work with their teams to set a clear, bespoke action plan of what needs to change to ensure a fast ROI
This is not just another zoom meeting! The digital platform not only has a Stage Area much like a main conference room onsite, but also boasts a Sessions Area for smaller discussions and interactive sessions, as well as a virtual exhibition space where delegates can explore the solutions that specialist suppliers have on offer, a one-to-one messaging platform for delegates to connect in private or public chatrooms and a virtual speed networking tool which automatically connects attendees to establish new professional relationships.
An exciting addition to an incredibly successful Gene Therapy event series, this new meeting has arrived at a time when the race to launch gene therapy products to market is well and truly on. The summit will equip attendees with all the tools needed to transform traditional medical affairs to launch the next generation of breakthrough medical affairs products.
To find out more about this event, view the full event guide here or visit www.genetherapy-medical-affairs.com.
Contact
General Enquiries & Registration Assistance
Gemma Ferriol
Delegate Acquisition Manager
Hanson Wade
(+1) 617 455 4188
info@hansonwade.com
Partnership Opportunities
Adam Harras Gummer
Senior Partnerships Director
Hanson Wade
(+1) 617 455 4188
sponsor@hasnonwade.com